✦ LIBER ✦

P.17.8 The co-formulation of pharmacological chaperone AT2220 with recombinant human acid alpha-glucosidase improves enzyme uptake and glycogen reduction in a mouse model of Pompe disease

✍ Scribed by Khanna, R.; Xu, S.; Pellegrino, L.; Lun, Y.; Soska, R.; Feng, J.; Frascella, M.; Garcia, A.; Flanagan, J.; Lockhart, D.J.; Valenzano, K.J.

Book ID: 123214494
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 57 KB
Volume: 23
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2013.06.658

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Exploring the use of a co-formulated pha

Exploring the use of a co-formulated pharmacological chaperone AT2220 with recombinant human acid alpha-glucosidase for Pompe disease

✍ Khanna, Richie; Xu, Su; Lun, Yi; Soska, Rebecca; Feng, Jessie; Frascella, Michel 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 57 KB

G.P.8.05 The pharmacological chaperone A

G.P.8.05 The pharmacological chaperone AT2220 increases mutant acid alpha-glucosidase levels and reduces tissue glycogen in a mouse model of Pompe disease

✍ R. Khanna; R. Soksa; J. Feng; Y. Lun; A.C. Powe; J. Flanagan; H. Do; D.J. Lockha 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 39 KB

T.P.44 The pharmacological chaperone AT2

T.P.44 The pharmacological chaperone AT2220 increases the stability of recombinant human acid α-glucosidase and leads to greater tissue uptake and glycogen reduction in a mouse model of Pompe disease

✍ Valenzano, K.J.; Feng, J.; Soska, R.; Pellegrino, L.; Frascella, M.; Lun, Y.; Fl 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 60 KB

Subcutaneous administration of recombina

Subcutaneous administration of recombinant human acid α-glucosidase co-formulated with the pharmacological chaperone AT2220 leads to lysosomal uptake of rhGAA and glycogen reduction in disease-relevant tissues of mice with Pompe disease

✍ Lun, Yi; Pellegrino, Lee; Xu, Su; Feng, Jessie; Soska, Rebecca; Frascella, Miche 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 48 KB